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 complex disease in
patients with advanced human immunodeficiency vi-
rus (HIV) infection. However, there is uncertainty about
whether prophylaxis should be continued in patients
whose CD4+ cell counts have increased substantial-




We conducted a multicenter, double-blind,
randomized trial of treatment with azithromycin (1200
mg weekly) as compared with placebo in HIV-infected
patients whose CD4+ cell counts had increased from
less than 50 to more than 100 per cubic millimeter in










A total of 520 patients entered the study;
the median CD4+ cell count at entry was 230 per cu-
bic millimeter. In 48 percent of the patients, the HIV
RNA value was below the level of quantification. The
median prior nadir CD4+ cell count was 23 per cubic
millimeter, and 65 percent of the patients had had an
acquired immunodeficiency syndrome–defining ill-
ness. During follow-up over a median period of 12





 complex disease in either group (95 percent con-
fidence interval for the rate of disease in each group,
0 to 1.5 episodes per 100 person-years). Three patients
in the azithromycin group (1.2 percent) and five in
the placebo group (1.9 percent) had bacterial pneu-
monia (relative risk in the azithromycin group, 0.60;
95 percent confidence interval, 0.14 to 2.50; P=0.48).
Neither the rate of progression of HIV disease nor the
mortality rate differed significantly between the two
groups. Adverse effects led to discontinuation of the
study drug in 19 patients assigned to receive azithro-
mycin (7.4 percent) and in 3 assigned to receive pla-




Azithromycin prophylaxis can safely
be withheld in HIV-infected patients whose CD4+ cell
counts have increased to more than 100 cells per cu-
bic millimeter in response to antiretroviral therapy.
(N Engl J Med 2000;342:1085-92.)
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HE identification of effective strategies to
prevent opportunistic infections has been an
important advance in the care of patients





 Primary prophylaxis is instituted on the
basis of CD4+ cell thresholds for increased risks of





 complex disease, a serious and life-





agents, including azithromycin, clarithromycin, and




and prophylaxis is recommended for all HIV-infected





 Azithromycin has been widely used
for this purpose because it can be administered in a
convenient weekly dose. Azithromycin prophylaxis













complex disease were performed, more potent anti-
retroviral regimens have been introduced that sup-





 Marked decreases in the incidence of major









 complex disease, have been re-




The question now is whether patients whose CD4+
cell counts have been below the threshold for the
initiation of prophylaxis against opportunistic infec-
tion should continue to receive prophylaxis once
their cell counts rise above the threshold. Because of
concern about the function of CD4+ cells in patients
receiving antiretroviral therapy, the 1997 guidelines
for the prevention of opportunistic infections recom-
mended continued prophylaxis despite an increase in
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We performed a study to determine whether pa-
tients whose CD4+ cell counts had increased sub-
stantially in response to antiretroviral therapy should











HIV-infected patients 13 years of age or older were eligible for
the study if they had had a CD4+ cell count of less than 50 per
cubic millimeter (at any time in the past), followed by a count of
more than 100 cells per cubic millimeter on two consecutive occa-
sions in response to antiretroviral therapy. Patients with a history





 complex disease, or a condition requiring treatment with agents




 complex were excluded.
The study was approved by the institutional review board at
each participating center, and written informed consent was ob-




The study was a randomized, double-blind clinical trial com-
paring the efficacy of azithromycin (Zithromax, Pfizer), given at a
dose of 1200 mg once weekly, with that of a matched placebo.
Patients were randomly assigned to the study groups in a 1:1 ra-
tio, with stratification according to the clinical center and accord-




complex disease at any time before enrollment. Patients whose
CD4+ cell counts fell below 50 per cubic millimeter after enroll-
ment were offered open-label azithromycin.
The sample size (850 patients) and the duration of follow-up
(27 months) were chosen to provide the study with 80 percent
power to detect a 40 percent difference in the primary end point
between the study groups (22.0 percent vs. 13.2 percent). We also
assumed that the death rate would be 34 percent at 27 months
and that 4 percent of the patients would be lost to follow-up.
 
End Points and Follow-up
 





 complex disease or confirmed or prob-
able bacterial pneumonia. One of two criteria had to be met for




 complex disease: a positive cul-
ture of a blood specimen or a specimen from another normally ster-
ile site or a positive culture of a specimen from a nonsterile site
with clinical evidence of dissemination. One of three criteria had
to be met for a diagnosis of confirmed bacterial pneumonia: his-
tologic evidence of bacterial pneumonia, a positive quantitative cul-
ture of a protected-brush specimen for a likely pathogen, or clin-
ical and radiographic abnormalities consistent with the diagnosis.
The third criterion had to be accompanied by at least one of two
additional types of evidence: a positive culture or Gram’s stain for a
likely pathogen in a blood specimen, a specimen from another nor-
mally sterile site, a bronchoalveolar-lavage specimen, or a lung as-
pirate or the predominance of such a pathogen in an adequate









Probable bacterial pneumonia was defined as clinical and radio-
graphic evidence (as described above), the absence of another di-
agnosis, and a response to antibiotic therapy.





 pneumonia, grade IV adverse events (i.e., severe and poten-
tially life-threatening events, as graded on a five-point scale devel-
oped by the Division of AIDS of the National Institute of Allergy
and Infectious Diseases), and toxic effects requiring permanent dis-
continuation of azithromycin or placebo. A clinical-events com-
mittee, which was unaware of the treatment assignments, reviewed




 complex disease and bacterial pneumonia
that were not confirmed.
Follow-up visits were scheduled for every four months. At each
visit, a clinical evaluation was performed to determine whether any
primary or secondary end points had occurred, and the CD4+ cell
count and HIV-1 RNA level were measured (by either a polymer-




The investigators were unaware of the interim results, which were
reviewed by an independent data and safety monitoring board.
On July 28, 1999, the board recommended closure of the study




 complex disease and bacte-
rial pneumonia.
The study groups were compared with use of the chi-square
test or Fisher’s exact test for categorical data and with use of Stu-
dent’s t-test for continuous data. Time-to-event analyses were per-
formed with proportional-hazards regression. All analyses were
performed on an intention-to-treat basis, and all reported P values
are two-sided. Exact 95 percent confidence intervals for incidence




Characteristics of the Patients
 
Between October 1997 and July 1999, 520 pa-
tients at 15 centers were enrolled in the study; 258
patients were randomly assigned to azithromycin, and
262 to placebo. The median prior nadir CD4+ cell
count was 23 per cubic millimeter. The median CD4+
cell count at base line was 230 per cubic millimeter.
The median count was higher in the placebo group
than in the azithromycin group (243 vs. 226 per cu-
bic millimeter, P=0.02). The two groups were oth-
erwise similar with regard to base-line characteristics
(Table 1). At enrollment, 50 percent of the patients
in whom HIV RNA was measured by PCR had less
than 400 copies per milliliter, and 37 percent of those
in whom HIV RNA was measured by a branched-
chain DNA assay had less than 500 copies per milli-
liter. Sixty-five percent of the patients had received a
clinical diagnosis of the acquired immunodeficiency





 pneumonia; and 14 percent had a history of bac-
terial pneumonia. At enrollment, 93 percent of the





 pneumonia; 69.4 percent of the patients in the
azithromycin group and 68.7 percent of those in the
placebo group were receiving trimethoprim–sulfa-
methoxazole (P=0.87). Sixty-nine percent of the pa-





plex disease. Of the 242 patients (47 percent) who





disease at base line, 210 were receiving azithromy-
cin, 26 clarithromycin, and 5 rifabutin. Similar pro-
portions of patients in the two groups had under-
gone pneumococcal vaccination (64.3 percent in the
azithromycin group and 69.9 percent in the placebo
group, P=0.18).
All the study participants were receiving antiretro-
viral therapy at enrollment, with 94 percent receiv-
ing regimens that included a protease inhibitor. At
12 months, 98 percent of the patients were receiving
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antiretroviral therapy, with 92 percent receiving reg-
imens that included a protease inhibitor. The antiret-
roviral regimens did not differ significantly between
the two study groups.
 
Duration of Follow-up and Study Treatment
 
At the time that the treatment assignments were
revealed, the median duration of follow-up was 12.7
months (range, 0.5 to 21.2) in the azithromycin group
and 12.0 months (range, 0.1 to 21.4) in the placebo
group. Seven patients (1.3 percent) were lost to fol-
low-up (four in the azithromycin group and three in
the placebo group).
Eight of the 258 patients in the azithromycin group
(3.1 percent) and 4 of the 262 patients in the place-
bo group (1.5 percent) received open-label azithro-
mycin during follow-up. Fifty-one patients in the az-
ithromycin group (19.8 percent) and 32 patients in
the placebo group (12.2 percent) discontinued the
assigned treatment but were not eligible for open-
label azithromycin (relative risk in the azithromycin





Confirmed or probable bacterial pneumonia devel-
oped in three patients in the azithromycin group (1.2
percent) and in five patients in the placebo group
(1.9 percent; relative risk in the azithromycin group,
0.60; 95 percent confidence interval, 0.14 to 2.50;




 complex disease. Bacterial pneumonia was
confirmed in two of the three patients in the azith-
romycin group and in three of the five patients in the
placebo group. The 95 percent confidence interval
for the rate of bacterial pneumonia was 0.2 to 3.5
episodes per 100 person-years in the azithromycin
group and 0.6 to 4.7 episodes per 100 person-years
in the placebo group. The 95 percent confidence in-




 complex disease in each
group was 0 to 1.5 episodes per 100 person-years.
 
Deaths and AIDS-Defining Events
 
In each group, five patients (1.9 percent) died.
Three patients died from liver failure, three from car-
diovascular disease, two from cancer, one from an
overdose of methadone, and one from wasting. In
addition, the progression of HIV disease (including
death) was reported in 14 patients assigned to receive
azithromycin (5.4 percent) and in 13 patients assigned
to receive placebo (5.0 percent) (Table 2). None of
the patients had cytomegalovirus disease, cryptococ-
cosis, histoplasmosis, Kaposi’s sarcoma, or progressive





 pneumonia, four of esophageal can-
didiasis, and one each of tuberculosis, toxoplasmosis,
AIDS-related dementia, and lymphoma. There were
47 cases of bacterial infections, which were distrib-
uted similarly in the two groups. The rates of events






sinusitis, and bacteremia) were low and did not differ
significantly between the two groups (Table 2).
 
Adverse Events and Discontinuation of Study Drugs
 
Grade IV adverse events occurred in 27 patients
in the azithromycin group (10.5 percent) and in 36
patients in the placebo group (13.7 percent; relative
risk in the azithromycin group, 0.73; P=0.22). Tox-
ic effects required discontinuation of the assigned
treatment in 19 patients in the azithromycin group
(7.4 percent) and in 3 patients in the placebo group
(1.1 percent; relative risk, 6.64; P=0.002) (Table 3).
Most toxic effects requiring discontinuation of the
study drug were grade II. In 11.6 percent of the pa-
tients assigned to receive azithromycin and in 5.3 per-
cent of those assigned to receive placebo, the study
drug was discontinued at the patient’s request (rela-
tive risk, 2.30; P=0.01). The blinded study drug was
discontinued because of a switch to open-label az-
ithromycin (in patients with CD4+ cell counts that
dropped below 50 per cubic millimeter) in 3.1 per-
 
*Plus–minus values are means ±SD.
†The lower limit of detection was 400 copies per milliliter with the PCR






















































Prior intravenous drug use (%) 17.5 17.2
Prior AIDS diagnosis (%) 67.4 62.6
Female sex (%) 11.2 13.4
Age (yr) 41.7±7.4 41.9±8.5





Prescribed «30 days before random-
ization
45.7 47.3
Prescribed >30 days before random-
ization
23.6 21.0
No prior use 30.6 31.7




































HIV RNA undetectable (%)† 47.1 48.5
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cent of the azithromycin group and in 1.5 percent of
the placebo group, because of death in 1.6 percent
of the azithromycin group and in 1.1 percent of the
placebo group, and for other reasons in 6.2 percent
of the azithromycin group and in 5.7 percent of the
placebo group (Table 3). In some cases, there was
more than one reason for discontinuation.
 
CD4+ Cell Counts and HIV RNA Levels
 
In both study groups, the average CD4+ cell count
rose during follow-up (Fig. 1). At 12 months, the av-
erage increase from base line in the CD4+ cell count
was 37.6 per cubic millimeter in the azithromycin
group and 40.7 per cubic millimeter in the placebo
group. During follow-up, 12 patients in the azithro-
 
*The relative risk of an event and the associated confidence interval (CI) and P value were derived
from a Cox proportional-hazards regression model. The relative risks shown are for the azithromycin
group as compared with the placebo group. For comparisons involving no events in one group, the










































Disseminated M. avium 
complex infection 
(confirmed)




3 1.2 5 2.0 0.60 (0.14–2.50) 0.48
Death 5 2.0 5 2.0 1.00 (0.29–3.46) 1.00
Progression of HIV dis-
ease (including death)
14 5.7 13 5.3 1.06 (0.50–2.25) 0.88
P. carinii pneumonia 3 1.0 3 1.0 0.97 (0.20–4.82) 0.97
Toxoplasmosis 0 0 1 0.3 — 1.00
Sinusitis 16 5.4 20 6.9 0.78 (0.41–1.51) 0.47
Bacteremia 2 0.7 0 0 — 0.25
*The relative risk of an event and the associated confidence interval (CI) and P value were derived
from a Cox proportional-hazards regression model. The relative risks shown are for the azithromycin
group as compared with the placebo group. For comparisons involving no events in one group, the
P values were calculated with Fisher’s exact test.
†Reasons for discontinuation were not mutually exclusive.














Grade IV adverse event 27 11.5 36 15.7 0.73 (0.44–1.20) 0.22
Discontinuation of study
drug
59 24.7 36 14.4 1.78 (1.18–2.70) 0.01
Reason for discontinua-
tion†
Toxicity 19 8.0 3 1.2 6.64 (1.97–22.46) 0.002
Grade I 3 1.3 1 0.4 3.17 (0.33–30.43) 0.32
Grade II 13 5.4 2 0.8 3.16 (1.54–30.31) 0.01
Grade III 1 0.4 0 0 — 0.50
Grade IV 1 0.4 0 0 — 0.50
Grade V 1 0.4 0 0 — 0.50
Death 4 1.7 3 1.2 1.39 (0.31–6.20) 0.67
Patient’s request 30 12.6 14 5.6 2.30 (1.22–4.34) 0.01
Switch to open-label 
azithromycin
8 3.3 4 1.6 2.28 (0.68–7.57) 0.18
Other 16 6.7 15 6.0 1.18 (0.58–2.38) 0.65
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mycin group (4.7 percent) and 10 patients in the
placebo group (3.8 percent) had a CD4+ cell count
of less than 50 per cubic millimeter on at least one
occasion.
The HIV RNA values declined slightly in both
groups. Figure 2 shows the proportions of patients
with values that were below the limit of detection at
base line and at months 4, 8, 12, and 16. Of the 216
patients in whom HIV RNA was measured by a PCR
assay at 12 months, 53 percent of those assigned to
receive azithromycin and 55 percent of those assigned
to receive placebo had an HIV RNA level of less
than 400 copies per milliliter. There were no signif-
icant differences in HIV RNA levels between the
two groups.
DISCUSSION
The results of our randomized, placebo-controlled
trial show that it is safe to withhold azithromycin
prophylaxis in HIV-infected patients whose CD4+
cell counts have risen to more than 100 per cubic
millimeter in response to antiretroviral therapy. Even
though our patients had advanced AIDS, there were
no cases of confirmed M. avium complex disease dur-
ing approximately 500 patient-years of follow-up, and
the rates of bacterial pneumonia were low in both
the placebo group and the azithromycin group.
The dramatic effect of improved immune function
on the rates of M. avium complex disease and bac-
terial pneumonia in our study can be recognized by
comparing the rates of these two disorders before ef-
fective antiretroviral therapy was available. In that era,
the rate of M. avium complex disease in patients with
a CD4+ cell count of 20 to 30 per cubic millimeter
(a value similar to the nadir count in the patients in
our study) was 20 to 30 percent per year.11,12 Even
with the use of clarithromycin or azithromycin as pro-
phylaxis, the annual risk of M. avium complex disease
in patients with a base-line CD4+ cell count of less
than 100 per cubic millimeter was 7 to 8 percent per
year.3-5 Similarly, rates of bacterial pneumonia were
much higher before the introduction of effective an-
tiretroviral therapy. For example, in one prospective
study, the rate of bacterial pneumonia was 10.8 ep-
isodes per 100 person-years among patients with a
base-line CD4+ cell count of less than 200 per cu-
bic millimeter and 2.8 episodes per 100 person-years
among those with a base-line count of more than
500 per cubic millimeter.13 Both groups in our study
had lower rates of bacterial pneumonia, even though
they had a median nadir CD4+ cell count of only
23 per cubic millimeter and a median base-line count
of 230 per cubic millimeter.
Our finding that it is safe to withhold azithromy-
cin prophylaxis in patients with a CD4+ cell count of
more than 100 per cubic millimeter in response to
antiretroviral therapy parallels the results of recent
studies of the safety of withdrawing prophylaxis
against P. carinii pneumonia in patients whose CD4+
cell counts have increased to more than 200 per cu-
bic millimeter. Two observational studies,14,15 two non-
randomized prospective studies,16,17 and the prelimi-
nary results of one randomized trial18 all indicate that
the withdrawal of primary prophylaxis against P. ca-
rinii pneumonia is safe in patients with a sufficient
increase in the CD4+ cell count in response to an-
Figure 1. Average CD4+ Cell Count at Base Line and during Follow-up in 520 HIV-Infected Patients Assigned
to Receive Azithromycin or Placebo. The bars represent 95 percent confidence intervals.
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tiretroviral therapy. The recently updated guidelines
recommend the discontinuation of prophylaxis against
M. avium complex and P. carinii pneumonia under
these circumstances, although in the case of M. avium
complex disease, the recommendation until now was
based only on observational studies.19
The rates of other opportunistic conditions were
also low in our study. The rate of P. carinii pneumo-
nia was 1.0 episode per 100 person-years, as compared
with 3.5 episodes per 100 person-years in the largest
trial of trimethoprim–sulfamethoxazole,20 the most
effective prophylactic agent.21 The rate of cytomeg-
alovirus disease in our study was 0 episodes per 100
person-years, as compared with 14 episodes per 100
person-years among similarly immunocompromised
patients who received ganciclovir prophylaxis in the
era before potent antiretroviral therapy was avail-
able.22,23 Although some investigators have postulat-
ed that progressive HIV infection causes irreversible
damage to the immune system,24 the low rates of all
opportunistic illnesses in our study demonstrate that
effective immunity can be restored with antiretrovi-
ral therapy, even in patients with nadir CD4+ cell
counts below 50 per cubic millimeter.
Despite the relative simplicity of azithromycin pro-
phylaxis, there are a number of reasons to defer anti-
microbial prophylaxis if the rate of the target oppor-
tunistic infection is low. Rates of antibiotic resistance
among common bacterial pathogens, such as Strep-
tococcus pneumoniae, have increased dramatically in
the past 10 years,25,26 and prior exposure to antibiot-
ics is a strong risk factor for infection with antibiotic-
resistant bacteria.27 Patients with advanced AIDS have
high rates of colonization and infection with antibi-
otic-resistant S. pneumoniae,28,29 probably in part be-
cause of the use of prophylaxis against M. avium com-
plex disease and P. carinii pneumonia.30 In one study
involving patients with HIV infection, both weekly
treatment with azithromycin and daily treatment with
clarithromycin were associated with the isolation of
macrolide-resistant respiratory flora in all the study
participants.31
In addition, polypharmacy carries the risk of drug
interactions and may reduce adherence to treatment
regimens.32 Finally, the risk of drug intolerance is a
reason for withholding prophylaxis. In our study, side
effects led to the discontinuation of the study drug
in 7 percent of the patients assigned to receive azith-
romycin but in only 1 percent of those assigned to
receive placebo.
Our study has several limitations. The patients had
a marked increase in the CD4+ cell count, from a
median previous nadir of 23 per cubic millimeter to
a median of 230 per cubic millimeter at the time of
enrollment. Furthermore, the CD4+ cell count con-
tinued to increase over the course of the study. It is
unclear whether the results of this study apply to pa-
tients with less dramatic increases in the CD4+ cell
Figure 2. Proportions of Patients in the Azithromycin and Placebo Groups Who Had Undetectable Levels of
HIV RNA.
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count or to patients in whom the CD4+ cell count
drops after an initial increase in response to antiret-
roviral therapy. In addition, our study cannot answer
the question of whether the recommended thresh-
old CD4+ cell count of less than 50 per cubic mil-
limeter should be used as a criterion for restarting
prophylaxis in this population. Until this question is
answered, prophylaxis against M. avium complex dis-
ease is recommended for all patients with a CD4+
cell count of less than 50 per cubic millimeter, as
specified by the current guidelines.19
In summary, our study shows that prophylaxis
against disseminated M. avium complex disease can
be safely withheld in patients with CD4+ cell counts
that have increased from less than 50 to more than
100 per cubic millimeter in response to antiretroviral
therapy, because the risk of disseminated M. avium
complex disease in this population is low. In addi-
tion, our study shows that azithromycin prophylaxis
does not significantly affect the rates of bacterial pneu-
monia, progression of HIV disease, or death in such
patients. These findings contribute to the efforts to
simplify treatment regimens and improve adherence
to them, decrease the risk of antimicrobial resistance,
and avoid adverse events associated with additional
medications.
Supported by a grant from the National Institute of Allergy and Infec-
tious Diseases.
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APPENDIX
The following centers and investigators participated in the study: AIDS
Research Alliance, Chicago — M. Diaz-Linares, R. Luskin-Hawk, C.
Peterson; AIDS Research Consortium of Atlanta, Atlanta — P. Couey, M.
Thompson, B. Weaver; Community Consortium of San Francisco, San
Francisco — S. Crawford, H. Lampiris, R. Scott; Denver Community Pro-
grams for Clinical Research on AIDS, Denver — B. Barber, D. Cohn, R.
Fernandez; Harlem AIDS Treatment Group, New York — C. Guity, S.
Barnaby, L. Fuentes; Henry Ford Hospital, Detroit — B. Braxton, B.
Campbell, L. Faber; Louisiana Community AIDS Program, New Orleans
— C.L. Besch, D. Mushatt, J. Osterberger; North Jersey Community Re-
search Initiative, Newark, N.J. — P. Andrew, N. Regevik, R. Roland; Part-
ners in Research New Mexico, Albuquerque — C. Angel, K. Hammer, J.
Magill; Philadelphia FIGHT, Philadelphia — P. Cooper, B. Gallagher, P.
Loynd; Richmond AIDS Consortium, Richmond, Va. — M. Britton, P.
Dodson, M. Howe; Research and Education Group, Portland, Oreg. — D.
Antoniskis, S. Peterson, S. Pierson; Southern New Jersey Clinical Trials,
Camden — K. Casey, D. Condoluci, J. Muratore; Washington Regional
AIDS Program, Washington, D.C. — B. Rashbaum, K. Shade, S. Zubairi;
and Wayne State University, Detroit — R. MacArthur, P. Reitenga, M. Yoder.
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